The Quality Overall Summary (QOS) is an element of a drug marketing application that provides a substantially condensed summary of the quality-related data provided in the submission. Regulators can use the QOS to more effectively assess applications and more rapidly comprehend the quality information in the context of patient risk, including the proposed control strategy and any other planned steps to mitigate that risk. Patients benefit from the greater assessment efficiency by having improved access to drugs that are designed and manufactured to consistently and safely fulfill claims in the label.
News & Trends
Procurar
Recentes
- The first harmonised standard under the EU AI Act is here
- PHARMA PACKAGE : Council adopts new rules for a fairer and more competitive EU pharmaceutical sector
- HTA Regulation – Commission selects first medical devices for joint clinical assessment
- PHARMACOVIGILANCE UPDATE | FDA E2B(R3) IMPLEMENTATION GUIDE — OCTOBER 2026
- updated PIC/S PI 006-4 guideline RECOMMENDATIONS ON QUALIFICATION AND VALIDATION
- Annual report of the Pharmacovigilance Inspectors Working Group for 2025
- European Medicines Agency post-authorisation procedural advice for users of the centralised procedure
- ACT EU workplan 2026 – 2027